The Belgian biotechnology company, Cardio3 BioSciences , a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces it has received authorization from the Belgian Federal Agency for Medicines and Health Products to begin its Congestive Heart failure Cardiopoietic ... (more)
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Cardio3-BioSciences-Receives-Authorization-to-Begi/ArticleNewsFeed/Article/detail/797473?ref=25
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Cardio3-BioSciences-Receives-Authorization-to-Begi/ArticleNewsFeed/Article/detail/797473?ref=25
No comments:
Post a Comment